e-journal
Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case–control study and updated meta-analysis
Aim: We investigated whether plasma levels of lysophosphatidic acid (LPA) could serve as a diagnostic indicatorfor assessing disease progression in ovarian cancer (OC) patients.
Material and Methods: In this study, we enrolled 98 patients with OC, 70 patients with benign ovarian tumors and 75 healthy controls. Plasma levels of LPA and cancer antigen 125 (CA-125) were measured in all study subjects. The diagnostic values of LPA and CA-125 plasma levels were evaluated and an updated metaanalysis was performed to examine the association between LPA plasma levels and OC progression. Statistical analyses were performed with SPSS 18.0 and R 3.1.0 software.
Results:
In our case–control study, OC patients showed significantly higher plasma LPA levels compared to
patients with benign tumors and healthy controls (all P< 0.05). Plasma LPA levels exhibited higher diagnostic sensitivity (P=0.008) and specificity (P=0.042) in detecting OC, compared to an established marker, CA-125.Notably, the sensitivity for early stage OC was significantly higher for plasma LPA levels in comparison toCA-125 (P0.05).
Conclusion:Plasma LPA levels are elevated in OC patients and correlate with disease progression. Further, LPA shows higher sensitivity and specificity in OC diagnosis, compared to CA-125, especially in early stage OC.
Tidak ada salinan data
Tidak tersedia versi lain